Tina Ritschel

Tina Ritschel

Auto-generated profile, based on publicly available information

Tina Ritschel

Janssen Vaccines & Prevention BV, Leiden, the Netherlands

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
JJJarek Juraszek
Jarek Juraszek
LRLucy Rutten
Lucy Rutten
SBSven Blokland
Sven Blokland
PBPascale Bouchier
Pascale Bouchier
RVRichard Voorzaat
Richard Voorzaat
JLJohannes PM Langedijk
Johannes PM Langedijk
The trimeric spike (S) protein of SARS-CoV-2 is the primary focus of most vaccine design and development efforts. Due to intrinsic instability typical of class I fusion proteins, S tends to prematurely refold to the post-fusion conformation, compromising immunogenic properties and prefusion trimer yields. To support ongoing vaccine development efforts, we report the structure-based design of soluble S trimers with increased yields and stabilities, based on introduction of single point mutations and disulfide-bridges. We identify regions critical for stability: the heptad repeat region 1, the SD1 domain and position 614 in SD2. We combine a minimal selection of mostly interprotomeric mutations to create a stable S-closed variant with a 6.4-fold higher expression than the parental construct while no longer containing a heterologous trimerization domain. The cryo-EM structure reveals a correctly folded, predominantly closed pre-fusion conformation. Highly stable and well producing S protein and the increased understanding of S protein structure will support vaccine development and serological diagnostics.

6 March 2018 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
HJHarrison G Jones
Harrison G Jones
TRTina Ritschel
Tina Ritschel
GPGabriel Pascual
Gabriel Pascual
JBJust P J Brakenhoff
Just P J Brakenhoff
EKElissa Keogh
Elissa Keogh
JMJason McLellan
Jason McLellan
Respiratory syncytial virus (RSV) is a major cause of severe lower respiratory tract infections in infants and the elderly, and yet there remains no effective treatment or vaccine. The surface of the virion is decorated with the fusion glycoprotein (RSV F) and the attachment glycoprotein (RSV G), which binds to CX3CR1 on human airway epithelial cells to mediate viral attachment and subsequent infection. RSV G is a major target of the humoral immune response, and antibodies that target the central conserved region of G have been shown to neutralize both subtypes of RSV and to protect against severe RSV disease in animal models. However, the molecular underpinnings for antibody recognition of this region have remained unknown. Therefore, we isolated two human antibodies directed against the central conserved region of RSV G and demonstrated that they neutralize RSV infection of human bronchial epithelial cell cultures in the absence of complement. Moreover, the antibodies protected cotton rats from severe RSV disease. Both antibodies bound with high affinity to a secreted form of RSV G as well as to a peptide corresponding to the unglycosylated central conserved region. High-resolution crystal structures of each antibody in complex with the G peptide revealed two distinct conformational epitopes that require proper folding of the cystine noose located in the C-terminal part of the central conserved region. Comparison of these structures with the structure of fractalkine (CX3CL1) alone or in complex with a viral homolog of CX3CR1 (US28) suggests that RSV G would bind to CX3CR1 in a mode that is distinct from that of fractalkine. Collectively, these results build on recent studies demonstrating the importance of RSV G in antibody-mediated protection from severe RSV disease, and the structural information presented here should guide the development of new vaccines and antibody-based therapies for RSV. Respiratory syncytial virus (RSV) is a common cause of bronchiolitis and pneumonia, and is a leading cause of infant deaths globally due to infectious disease. Despite decades of research, there is still no vaccine or widespread treatment for RSV. In this study, we isolated two antibodies that bind to the central conserved region of the viral attachment glycoprotein, RSV G. The antibodies effectively neutralize both subtypes of RSV and protect RSV-challenged animals from severe disease. We also determined high-resolution crystal structures of each antibody in complex with the central conserved region of RSV G to gain a better understanding of how these antibodies bind to RSV G and how they neutralize the virus. Because RSV G is a small folded domain bounded by unstructured mucin-like domains, structural elucidation of the central conserved region provides atomic-level information for the complete folded portion of RSV G. The results presented here will help develop effective antibodies for passive prophylaxis as well as guide efforts to design vaccines that elicit broadly neutralizing antibodies against RSV G.

7 February 2022 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
FMFin J. Milder
Fin J. Milder
MJMandy Jongeneelen
Mandy Jongeneelen
TRTina Ritschel
Tina Ritschel
PBPascale Bouchier
Pascale Bouchier
IBIlona J. M. Bisschop
Ilona J. M. Bisschop
JLJohannes PM Langedijk
Johannes PM Langedijk
Significance: Influenza hemagglutinin (HA) is a prototypical class I fusion protein and a major component of current flu vaccines. HA is a metastable glycoprotein and undergoes conformational changes to the so-called postfusion state. Stabilization of the prefusion conformations of fusion proteins has proven to be a key success factor for the induction of efficacious immune response and stabilization has become a grand challenge in structural vaccinology. The study shows that three stabilizing mutations in two important pH-sensitive switch regions involved in the early refolding process impede refolding of the prefusion HA. Based on the substitutions of these highly conserved and buried HA residues a generally applicable stabilization strategy for all subtypes of group 1 and 2 influenza A HA was developed.

25 July 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
MBMark J. G. Bakkers
Mark J. G. Bakkers
TRTina Ritschel
Tina Ritschel
MTMachteld Tiemessen
Machteld Tiemessen
JDJacobus Dijkman
Jacobus Dijkman
AZAngelo A. Zuffianò
Angelo A. Zuffianò
JLJohannes PM Langedijk
Johannes PM Langedijk
The prefusion conformation of human metapneumovirus fusion protein (hMPV Pre-F) is critical for eliciting the most potent neutralizing antibodies and is the preferred immunogen for an efficacious vaccine against hMPV respiratory infections. Here we show that an additional cleavage event in the F protein allows closure and correct folding of the trimer. We therefore engineered the F protein to undergo double cleavage, which enabled screening for Pre-F stabilizing substitutions at the natively folded protomer interfaces. To identify these substitutions, we developed an AI convolutional classifier that successfully predicts complex polar interactions often overlooked by physics-based methods and visual inspection. The combination of additional processing, stabilization of interface regions and stabilization of the membrane-proximal stem, resulted in a Pre-F protein vaccine candidate without the need for a heterologous trimerization domain that exhibited high expression yields and thermostability. Cryo-EM analysis shows the complete ectodomain structure, including the stem, and a specific interaction of the newly identified cleaved C-terminus with the adjacent protomer. Importantly, the protein induces high and cross-neutralizing antibody responses resulting in near complete protection against hMPV challenge in cotton rats, making the highly stable, double-cleaved hMPV Pre-F trimer an attractive vaccine candidate.

Verified
Other
Open access
SVStefan Verhoeven
Stefan Verhoeven
MVMarton Vass
Marton Vass
CGChris De Graaf
Chris De Graaf
RMRoss McGuire
Ross McGuire
TRTina Ritschel
Tina Ritschel
Library to interact with Kripo fragment, fingerprint and similarity data files. KRIPO stands for Key Representation of Interaction in POckets, see reference for more information. Changed Fixed several Codacy warnings.